Expression of galectin-3, CD138, p16INK4a, and TTF-1 in mucinous bronchioloalveolar adenocarcinoma after hodgkin lymphoma

Suhail Al-Salam, Moueid Al-Ashari

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Bronchioloalveolar carcinoma (BAC) is a subset of lung adenocarcinoma that has a distinct clinical presentation, tumor biology, response to therapy, and prognosis compared with other subtypes of non-small-cell lung carcinoma. BAC disproportionately affects women, never-smokers, and is characterized by growth along alveolar septae without evidence of stromal, vascular, or pleural invasion. Microscopically, BACs have been divided into mucinous, nonmucinous, and mixed types. We describe a case of young female who received radiation therapy to the mediastinum and chemotherapy for Hodgkin lymphoma and now develops mucinous bronchioalveolar adenocarcinoma of the left lung which to the best of our knowledge has not been previously described after radiotherapy and chemotherapy for Hodgkin lymphoma. The tumor cells express Galectin-3, CD138, p16, thyroid transcription factor-1, cytokeratin 7, epithelial membrane antigen, carcinoembryonic antigen, E-cadherin, neuron-specific enolase, and S100 whereas no expression of cytokeratin 20, calretinin, and CDX2 is seen.

Original languageEnglish
Pages (from-to)351-356
Number of pages6
JournalApplied Immunohistochemistry and Molecular Morphology
Volume17
Issue number4
DOIs
Publication statusPublished - Jul 2009

Keywords

  • Bronchioloalveolar adenocarcinoma
  • Hodgkin lymphoma
  • Lung

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Medical Laboratory Technology

Fingerprint

Dive into the research topics of 'Expression of galectin-3, CD138, p16INK4a, and TTF-1 in mucinous bronchioloalveolar adenocarcinoma after hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this